SAN DIEGO, April 13, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for both TRC105 and TRC102 at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 18-22, 2015, in Philadelphia, PA.
Dr. Lukas Hawinkels and colleagues of the Leiden University Medical Center will present preclinical data for TRC105. The presentation details are as follows:
| Abstract Number: | 4130 |
| Abstract Title: | Dual Targeting of VEGF and Endoglin Inhibits Tumor Angiogenesis and Metastatic Spread |
| Presenter: | Madelon Paauwe, Leiden University Medical Center, Leiden, Netherlands |
| Location: | Section 17, Poster Board Number 21 |
| Date: | Tuesday, April 21, 2015 |
| Times: | 1:00pm – 5:00pm EDT |
Dr. Alice Chen and colleagues of the National Cancer Institute will present data from an ongoing Phase 1 clinical trial of TRC102 in combination with temozolomide. The presentation details are as follows:
| Abstract Number: | CT316 |
| Abstract Title: | A Phase 1 Trial of Oral TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors |
| Presenter: | Woondong Jeong, MD, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD |
| Location: | Section 24, Poster Board Number 16 |
| Date: | Tuesday, April 21, 2015 |
| Times: | 8:00am – 12:00pm EDT |
About TRC105
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in age‐related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
About TRC102
TRC102 is a novel, clinical stage small molecule inhibitor of the DNA base excision repair pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in clinical trials sponsored by both the National Cancer Institute and Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.